A Phase 4 interventional study of tofacitinib and tofacitinib in Arthritis, Rheumatoid, sponsored by Pfizer. Completed at 345 sites in 30 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-08-17.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 2nd largest by enrollment, is one of 3 that started in 2014, is one of 12 in phase 4, and was the 22nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Shaikh Zayed Hospital, Lahore · Sites in Pakistan
Ages 50–85
University Hospital, Toulouse · Sites in France
Ages 18–65
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Marie Hudson, MD · Sites in Canada
Ages 18+
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,372 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 170 across the 43 interventional studies. Of the 30 that completed or were terminated, 23 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 43 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
152 studies in Arthritis, Rheumatoid by Pfizer: 2 open now, 2 under way, none of them phase 3. Of 149 finished, 105 (70%) have results posted.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 2nd largest by enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2014, is one of 17 in phase 4, and was the 111th registered.
Pfizer’s Arthritis, Rheumatoid studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 152 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tofacitinib
Drug: tofacitinib
TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.
Biological: adalimumab · Biological: etanercept
Oral tablet, 5 mg BID
Oral tablet, 10 mg BID
Pre-filled syringe, 40 mg subcutaneous injection, every other week
Also known as: Humira
Pre-filled syringe, 50 mg subcutaneous injection, every week
Also known as: Enbrel
Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC)
Incidence rate (number of participants with event per 100 participant year \[PY\]) was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Malignancy events, excluding NMSC were adjudicated by a steering committee. The risk period (RP) was the last contact date. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Time frame: Baseline up to last contact date (maximum up to 72 months)
Incidence Rate of Adjudicated Major Adverse Cardiovascular Events (MACE)
MACE included the cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke of any classification, including reversible focal neurologic defects with imaging evidence of a new cerebral lesion consistent with ischemia or hemorrhage. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Time frame: Baseline up to last contact date (maximum up to 72 months)
Incidence Rate of Non-fatal Stroke
Non-fatal stroke included reversible focal neurologic defects with imaging evidence of a new cerebral lesion consistent with ischemia or hemorrhage. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Time frame: Baseline up to last contact date (maximum up to 72 months)
Incidence Rate of Non-fatal Myocardial Infarction
Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Time frame: Baseline up to last contact date (maximum up to 72 months)
Incidence Rate of Adjudicated Opportunistic Infection Events Including Tuberculosis
Opportunistic infections (OI) were reviewed and adjudicated by the opportunistic infection review committee (OIRC). Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Time frame: Baseline up to last contact date (maximum up to 72 months)
Incidence Rate of Adjudicated Hepatic Events
Hepatic events (adjudicated) included drug-induced liver injury (DILI) - probable, highly likely and definite, DILI - listed separately, DILI - cases meeting classification and severity, participants with elevations of transaminase levels greater than (\>) 1\* upper limit of normal (ULN), greater than or equal to (\>=) 3\*ULN, \>=5\*ULN (based on laboratory values). Incidence rate was the total number of participants with admissible events divided by total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was minimum of The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. Last contact date was maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). In case of death, last contact date was death date. First events counted within RP. Participant did not have an event or had an event outside risk period were censored at end of RP.
Time frame: Baseline up to last contact date (maximum up to 72 months)
Incidence Rate of Adjudicated Cardiovascular Events Other Than Major Adverse Cardiovascular Events (MACE)
Cardiovascular events (adjudicated) were death (coronary and non-coronary), MI, all coronary revascularization, unstable angina, new ischemic heart disease, stroke (fatal and non-fatal), transient ischemic attack (TIA), congestive heart failure (CHF), peripheral arterial vascular disease (PAVD), deep vein thrombosis, pulmonary embolism, arterial embolism, arterial thrombosis. Incidence rate was total number of participants with admissible events divided by total (for all qualifying participants) time at risk for cohort/treatment group of interest. Risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. Last contact date was maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). In case of death, last contact date was death date. First events counted within RP. Participant did not have an event or had an event outside risk period were censored at end of RP.
Time frame: Baseline up to last contact date (maximum up to 72 months)
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE was any untoward medical occurrence post treatment; event need not necessarily had causal relationship with treatment or usage. SAE: any untoward medical occurrence at any dose: resulted in death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly. TEAE: event that occurred for first time during effective duration of treatment and not seen prior to start of treatment or event seen prior to start of treatment but increase in severity during treatment. Risk period (RP) for AE: minimum of last contact date or last study treatment dose date+28 days. RP for SAEs: last contact date. Last contact date was maximum: AE start, AE stop, last study visit, withdrawal and telephone contact. In case of death, last contact was death date. First events counted within RP. Participant did not have event or had event outside risk period were censored at end of RP.
Time frame: AEs: Baseline up to minimum of last contact date or last study treatment dose date+28 days (maximum up to 72 months); SAEs: Baseline up to minimum of last contact date (maximum up to 72 months)
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
Clinically significant laboratory abnormalities: Hematology: hemoglobin, hematocrit, erythrocytes with primary criteria as less than \[\<\] 0.8\* lower limit of normal \[LLN\]), platelets (\<0.5\* LLN; \>1.75\* ULN), leukocytes (\<0.6\*LLN; \>1.5\*ULN), lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes (\<0.8\*LLN; \>1.2\*ULN), eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes (\>1.2\*ULN); urinalysis: urine glucose, urine protein, urine hemoglobin, and leukocyte esterase (\>=1); chemistry: bilirubin, indirect bilirubin (\>1.5\*ULN) aspartate aminotransferase, alanine aminotransferase (\>3.0\*ULN), creatinine, triglycerides, cholesterol (\>1.3\*ULN) and HDL cholesterol (\<0.8\*LLN). Risk period (RP) was minimum of last contact date or last study treatment dose date+28 days. Last contact date was (date of death or maximum of dates: AE start, AE stop, last study visit, withdrawal, telephone contact). Participants without event or event outside RP were censored at end of RP.
Time frame: Baseline up to last contact date (maximum up to 72 months)
Incidence Rate of Adjudicated All-Cause Deaths
All-cause death was defined as the death due to any cause during the course of study. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Incidence rate of all-cause deaths (adjudicated by Adjudication Committee) was reported in this outcome measure. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Time frame: Baseline up to last contact date (maximum up to 72 months)
Number of Participants With Reasons For Permanent or Temporary Discontinuation of Study Medication
Number of participants who permanent or temporary discontinued study medication due to any AE, treatment related AEs, Coronavirus disease 2019 (COVID 19) related AEs, and herpes zoster were reported. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Time frame: Baseline up to last contact date (maximum up to 72 months)
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) C-reactive Protein (CRP) at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
DAS28 is a measure of disease activity in participants with rheumatoid arthritis based on a 28-joint assessment. DAS28-4 (CRP) was calculated from number of painful joints out of 28 joints (TJC28) and number of swollen joints out of 28 joints (SJC28), CRP (milligrams per liter \[mg/L\]) and patient's global assessment of disease activity (PtGA) on a 100 mm Visual Analog Scale (VAS) (scores ranging from 0 millimeter \[mm\] \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (CRP) score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 indicates low disease activity and \> 3.2 to \<=5.1 indicates moderate disease activity, \>5.1 indicates high disease activity, and DAS28-4 (CRP) \< 2.6 indicates remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96; ln = natural logarithm, sqrt = square root.
Time frame: Baseline, Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
Change From Baseline in Simplified Disease Activity Index (SDAI) Score at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and physician's global assessment of health (PhyGA) both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.
Time frame: Baseline, Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.
Time frame: Baseline, Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
Percentage of Participants Who Achieved Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria
ACR-EULAR Boolean-based definition of remission participant must satisfy all of the following: TJC28 \<=1, SJC28 \<=1, CRP \<=10 mg/L, PtGA on a 0-100 mm scale, higher scores indicate greater affection due to disease activity.
Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Percentage of Participants With Simplified Disease Activity Index (SDAI) Less Than or Equal to (<=) 3.3
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.
Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Percentage of Participants With Clinical Disease Activity Index (CDAI) <=2.8
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.
Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Percentage of Participants With Simplified Disease Activity Index (SDAI) <=11
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.
Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Percentage of Participants With Clinical Disease Activity Index (CDAI) <=10
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.
Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Percentage of Participants With Disease Activity Score 28-4 (DAS28-4) C-reactive Protein (CRP) <=3.2
DAS28 is a measure of disease activity in participants with rheumatoid arthritis based on a 28-joint assessment. DAS28-4 (CRP) was calculated from number of painful joints out of 28 joints (TJC28) and number of swollen joints out of 28 joints (SJC28), CRP (mg/L) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (CRP) score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 indicates low disease activity and \> 3.2 to \<=5.1 indicates moderate disease activity, \>5.1 indicates high disease activity, and DAS28-4 (CRP) \< 2.6 indicates remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96.
Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Number of Participants With an American College of Rheumatology 20 Percent (%) (ACR20) Response
ACR20 response is a \>= 20% improvement in TJC (28) and SJC (28) and \>=20% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.
Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Number of Participants With an American College of Rheumatology 50% (ACR50) Response
ACR50 response is a \>= 50% improvement in TJC (28) and SJC (28) and \>=50% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.
Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Number of Participants With an American College of Rheumatology 70% (ACR70) Response
ACR70 response is a \>= 70% improvement in TJC (28) and SJC (28) and \>=70% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.
Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.
Time frame: Baseline, Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
| Milestone | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Started | 1457 | 1457 | 1458 |
| Treated | 1455 | 1456 | 1451 |
| Completed | 1053 | 998 | 1060 |
| Not completed | 404 | 459 | 398 |
| Withdrew: Death | 49 | 66 | 38 |
| Withdrew: Lost to follow-up | 38 | 35 | 40 |
| Withdrew: Global deterioration of health status | 1 | 0 | 0 |
| Withdrew: Other | 32 | 30 | 24 |
| Withdrew: Withdrawal by subject | 282 | 327 | 289 |
| Withdrew: Randomized but not treated | 2 | 1 | 7 |
Incidence rate (number of participants with event per 100 participant year \[PY\]) was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Malignancy events, excluding NMSC were adjudicated by a steering committee. The risk period (RP) was the last contact date. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
| participants with event/100 PY | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | All Tofacitinib | TNFi |
|---|---|---|---|---|
| Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC) | 1.13 (0.87 to 1.45) | 1.13 (0.86 to 1.45) | 1.13 (0.94 to 1.35) | 0.77 (0.55 to 1.04) |
MACE included the cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke of any classification, including reversible focal neurologic defects with imaging evidence of a new cerebral lesion consistent with ischemia or hemorrhage. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
| participants with event/100 PY | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | All Tofacitinib | TNFi |
|---|---|---|---|---|
| Incidence Rate of Adjudicated Major Adverse Cardiovascular Events (MACE) | 0.91 (0.67 to 1.21) | 1.05 (0.78 to 1.38) | 0.98 (0.79 to 1.19) | 0.73 (0.52 to 1.01) |
Non-fatal stroke included reversible focal neurologic defects with imaging evidence of a new cerebral lesion consistent with ischemia or hemorrhage. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
| participants with event/100 PY | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Incidence Rate of Non-fatal Stroke | 0.27 (0.15 to 0.45) | 0.33 (0.19 to 0.53) | 0.34 (0.20 to 0.54) |
Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
| participants with event/100 PY | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Incidence Rate of Non-fatal Myocardial Infarction | 0.37 (0.22 to 0.57) | 0.33 (0.19 to 0.53) | 0.16 (0.07 to 0.31) |
Opportunistic infections (OI) were reviewed and adjudicated by the opportunistic infection review committee (OIRC). Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
| participants with event/100 PY | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Incidence Rate of Adjudicated Opportunistic Infection Events Including Tuberculosis | 0.76 (0.54 to 1.04) | 0.91 (0.66 to 1.22) | 0.42 (0.26 to 0.64) |
Hepatic events (adjudicated) included drug-induced liver injury (DILI) - probable, highly likely and definite, DILI - listed separately, DILI - cases meeting classification and severity, participants with elevations of transaminase levels greater than (\>) 1\* upper limit of normal (ULN), greater than or equal to (\>=) 3\*ULN, \>=5\*ULN (based on laboratory values). Incidence rate was the total number of participants with admissible events divided by total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was minimum of The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. Last contact date was maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). In case of death, last contact date was death date. First events counted within RP. Participant did not have an event or had an event outside risk period were censored at end of RP.
| participants with event/100 PY | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Incidence Rate of Adjudicated Hepatic Events | 0.90 (0.66 to 1.20) | 1.51 (1.18 to 1.91) | 0.70 (0.49 to 0.97) |
Cardiovascular events (adjudicated) were death (coronary and non-coronary), MI, all coronary revascularization, unstable angina, new ischemic heart disease, stroke (fatal and non-fatal), transient ischemic attack (TIA), congestive heart failure (CHF), peripheral arterial vascular disease (PAVD), deep vein thrombosis, pulmonary embolism, arterial embolism, arterial thrombosis. Incidence rate was total number of participants with admissible events divided by total (for all qualifying participants) time at risk for cohort/treatment group of interest. Risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. Last contact date was maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). In case of death, last contact date was death date. First events counted within RP. Participant did not have an event or had an event outside risk period were censored at end of RP.
| participants with event/100 PY | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Incidence Rate of Adjudicated Cardiovascular Events Other Than Major Adverse Cardiovascular Events (MACE) | 1.21 (0.92 to 1.55) | 1.45 (1.13 to 1.83) | 1.05 (0.78 to 1.38) |
AE was any untoward medical occurrence post treatment; event need not necessarily had causal relationship with treatment or usage. SAE: any untoward medical occurrence at any dose: resulted in death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly. TEAE: event that occurred for first time during effective duration of treatment and not seen prior to start of treatment or event seen prior to start of treatment but increase in severity during treatment. Risk period (RP) for AE: minimum of last contact date or last study treatment dose date+28 days. RP for SAEs: last contact date. Last contact date was maximum: AE start, AE stop, last study visit, withdrawal and telephone contact. In case of death, last contact was death date. First events counted within RP. Participant did not have event or had event outside risk period were censored at end of RP.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| AEs | 1333 | 1344 | 1308 |
| SAEs | 373 | 420 | 339 |
Clinically significant laboratory abnormalities: Hematology: hemoglobin, hematocrit, erythrocytes with primary criteria as less than \[\<\] 0.8\* lower limit of normal \[LLN\]), platelets (\<0.5\* LLN; \>1.75\* ULN), leukocytes (\<0.6\*LLN; \>1.5\*ULN), lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes (\<0.8\*LLN; \>1.2\*ULN), eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes (\>1.2\*ULN); urinalysis: urine glucose, urine protein, urine hemoglobin, and leukocyte esterase (\>=1); chemistry: bilirubin, indirect bilirubin (\>1.5\*ULN) aspartate aminotransferase, alanine aminotransferase (\>3.0\*ULN), creatinine, triglycerides, cholesterol (\>1.3\*ULN) and HDL cholesterol (\<0.8\*LLN). Risk period (RP) was minimum of last contact date or last study treatment dose date+28 days. Last contact date was (date of death or maximum of dates: AE start, AE stop, last study visit, withdrawal, telephone contact). Participants without event or event outside RP were censored at end of RP.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Number of Participants With Clinically Significant Abnormal Laboratory Parameters | 238 | 252 | 167 |
All-cause death was defined as the death due to any cause during the course of study. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Incidence rate of all-cause deaths (adjudicated by Adjudication Committee) was reported in this outcome measure. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
| participants with event/100 PY | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Deaths-Total | 0.50 (0.33 to 0.74) | 0.80 (0.57 to 1.09) | 0.34 (0.20 to 0.54) |
| Deaths - Infections | 0.08 (0.02 to 0.20) | 0.18 (0.08 to 0.35) | 0.06 (0.01 to 0.17) |
| Deaths - Cardiovascular Events | 0.25 (0.13 to 0.43) | 0.41 (0.25 to 0.63) | 0.20 (0.10 to 0.36) |
| Deaths - Malignancies | 0.10 (0.03 to 0.23) | 0.00 (0.00 to 0.08) | 0.02 (0.00 to 0.11) |
| Deaths - Other Causes | 0.08 (0.02 to 0.20) | 0.21 (0.10 to 0.38) | 0.06 (0.01 to 0.17) |
Number of participants who permanent or temporary discontinued study medication due to any AE, treatment related AEs, Coronavirus disease 2019 (COVID 19) related AEs, and herpes zoster were reported. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Permanent discontinuation: AE | 210 | 304 | 210 |
| Temporary discontinuation: AEs | 665 | 736 | 576 |
| Permanent discontinuation: treatment related AE | 111 | 179 | 114 |
| Temporary discontinuation: treatment related AE | 407 | 458 | 297 |
| Permanent discontinuation: COVID-19 Related AEs | 0 | 1 | 0 |
| Temporary discontinuation: COVID-19 Related AEs | 0 | 1 | 1 |
| Permanent discontinuation: Herpes Zoster | 6 | 13 | 2 |
| Temporary discontinuation: Herpes Zoster | 104 | 110 | 33 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis based on a 28-joint assessment. DAS28-4 (CRP) was calculated from number of painful joints out of 28 joints (TJC28) and number of swollen joints out of 28 joints (SJC28), CRP (milligrams per liter \[mg/L\]) and patient's global assessment of disease activity (PtGA) on a 100 mm Visual Analog Scale (VAS) (scores ranging from 0 millimeter \[mm\] \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (CRP) score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 indicates low disease activity and \> 3.2 to \<=5.1 indicates moderate disease activity, \>5.1 indicates high disease activity, and DAS28-4 (CRP) \< 2.6 indicates remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96; ln = natural logarithm, sqrt = square root.
| units on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Change at Month 2 | -2.00 ± 0.03 | -2.14 ± 0.03 | -1.89 ± 0.03 |
| Change at Month 3 | -2.28 ± 0.03 | -2.42 ± 0.03 | -2.19 ± 0.03 |
| Change at Month 6 | -2.50 ± 0.03 | -2.68 ± 0.03 | -2.40 ± 0.03 |
| Change at Month 9 | -2.64 ± 0.03 | -2.80 ± 0.03 | -2.54 ± 0.03 |
| Change at Month 12 | -2.70 ± 0.03 | -2.85 ± 0.03 | -2.60 ± 0.03 |
| Change at Month 15 | -2.78 ± 0.03 | -2.93 ± 0.03 | -2.67 ± 0.03 |
| Change at Month 18 | -2.78 ± 0.03 | -2.95 ± 0.03 | -2.76 ± 0.03 |
| Change at Month 21 | -2.82 ± 0.03 | -2.97 ± 0.03 | -2.76 ± 0.03 |
| Change at Month 24 | -2.82 ± 0.03 | -2.99 ± 0.03 | -2.77 ± 0.03 |
| Change at Month 27 | -2.91 ± 0.03 | -3.03 ± 0.03 | -2.81 ± 0.03 |
| Change at Month 30 | -2.92 ± 0.03 | -3.03 ± 0.03 | -2.89 ± 0.03 |
| Change at Month 33 | -2.89 ± 0.03 | -3.03 ± 0.03 | -2.89 ± 0.03 |
| Change at Month 36 | -2.91 ± 0.03 | -2.98 ± 0.03 | -2.88 ± 0.03 |
| Change at Month 39 | -2.96 ± 0.03 | -2.97 ± 0.03 | -2.91 ± 0.03 |
| Change at Month 42 | -2.95 ± 0.03 | -3.05 ± 0.03 | -2.93 ± 0.03 |
| Change at Month 45 | -2.94 ± 0.04 | -2.96 ± 0.04 | -2.97 ± 0.04 |
| Change at Month 48 | -2.98 ± 0.04 | -2.99 ± 0.04 | -2.93 ± 0.04 |
| Change at Month 51 | -3.00 ± 0.04 | -2.95 ± 0.04 | -2.96 ± 0.04 |
| Change at Month 54 | -2.99 ± 0.04 | -3.01 ± 0.05 | -2.99 ± 0.05 |
| Change at Month 57 | -2.97 ± 0.05 | -2.93 ± 0.05 | -3.02 ± 0.05 |
| Change at Month 60 | -3.09 ± 0.06 | -2.94 ± 0.06 | -3.01 ± 0.06 |
| Change at Month 63 | -3.07 ± 0.08 | -2.99 ± 0.07 | -3.05 ± 0.08 |
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and physician's global assessment of health (PhyGA) both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.
| units on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Change at Month 2 | -22.95 ± 0.33 | -23.84 ± 0.33 | -22.24 ± 0.33 |
| Change at Month 3 | -25.73 ± 0.30 | -26.81 ± 0.30 | -25.26 ± 0.30 |
| Change at Month 6 | -27.63 ± 0.28 | -28.93 ± 0.28 | -27.21 ± 0.28 |
| Change at Month 9 | -28.81 ± 0.28 | -30.07 ± 0.28 | -28.29 ± 0.28 |
| Change at Month 12 | -29.56 ± 0.27 | -30.46 ± 0.27 | -28.71 ± 0.27 |
| Change at Month 15 | -30.20 ± 0.25 | -31.15 ± 0.26 | -29.30 ± 0.26 |
| Change at Month 18 | -30.14 ± 0.26 | -31.29 ± 0.26 | -30.18 ± 0.26 |
| Change at Month 21 | -30.42 ± 0.26 | -31.46 ± 0.26 | -30.36 ± 0.26 |
| Change at Month 24 | -30.51 ± 0.26 | -31.56 ± 0.26 | -30.33 ± 0.26 |
| Change at month 27 | -31.16 ± 0.25 | -31.85 ± 0.26 | -30.53 ± 0.26 |
| Change at Month 30 | -31.27 ± 0.25 | -32.02 ± 0.25 | -31.24 ± 0.25 |
| Change at Month 33 | -31.06 ± 0.26 | -31.91 ± 0.26 | -31.20 ± 0.26 |
| Change at Month 36 | -31.26 ± 0.26 | -31.52 ± 0.27 | -31.09 ± 0.26 |
| Change at Month 39 | -31.77 ± 0.25 | -31.51 ± 0.26 | -31.36 ± 0.26 |
| Change at Month 42 | -31.62 ± 0.27 | -32.09 ± 0.28 | -31.24 ± 0.27 |
| Change at Month 45 | -31.27 ± 0.29 | -31.67 ± 0.30 | -31.85 ± 0.30 |
| Change at Month 48 | -31.87 ± 0.31 | -31.59 ± 0.32 | -31.68 ± 0.32 |
| Change at Month 51 | -32.15 ± 0.33 | -31.52 ± 0.34 | -31.72 ± 0.34 |
| Change at Month 54 | -31.91 ± 0.33 | -32.33 ± 0.35 | -31.95 ± 0.35 |
| Change at Month 57 | -31.58 ± 0.41 | -31.61 ± 0.42 | -31.98 ± 0.42 |
| Change at Month 60 | -32.84 ± 0.46 | -31.57 ± 0.46 | -32.23 ± 0.48 |
| Change at Month 63 | -32.27 ± 0.63 | -32.12 ± 0.62 | -32.27 ± 0.66 |
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.
| units on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Change at Month 2 | -21.99 ± 0.32 | -22.84 ± 0.32 | -21.30 ± 0.32 |
| Change at Month 3 | -24.76 ± 0.29 | -25.77 ± 0.29 | -24.29 ± 0.30 |
| Change at Month 6 | -26.59 ± 0.27 | -27.82 ± 0.28 | -26.21 ± 0.28 |
| Change at Month 9 | -27.78 ± 0.27 | -29.03 ± 0.27 | -27.30 ± 0.27 |
| Change at Month 12 | -28.52 ± 0.26 | -29.38 ± 0.26 | -27.73 ± 0.26 |
| Change at Month 15 | -29.17 ± 0.25 | -30.06 ± 0.25 | -28.38 ± 0.25 |
| Change at Month 18 | -29.12 ± 0.25 | -30.21 ± 0.26 | -29.15 ± 0.25 |
| Change at Month 21 | -29.45 ± 0.25 | -30.49 ± 0.26 | -29.40 ± 0.25 |
| Change at Month 24 | -29.54 ± 0.25 | -30.49 ± 0.26 | -29.39 ± 0.25 |
| Change at Month 27 | -30.16 ± 0.24 | -30.82 ± 0.25 | -29.54 ± 0.25 |
| Change at Month 30 | -30.27 ± 0.24 | -30.99 ± 0.25 | -30.24 ± 0.25 |
| Change at Month 33 | -30.05 ± 0.25 | -30.85 ± 0.25 | -30.23 ± 0.25 |
| Change at Month 36 | -30.29 ± 0.25 | -30.50 ± 0.26 | -30.14 ± 0.25 |
| Change at Month 39 | -30.78 ± 0.24 | -30.49 ± 0.25 | -30.35 ± 0.25 |
| Change at Month 42 | -30.66 ± 0.26 | -31.05 ± 0.27 | -30.25 ± 0.26 |
| Change at Month 45 | -30.28 ± 0.28 | -30.68 ± 0.29 | -30.83 ± 0.29 |
| Change at Month 48 | -30.85 ± 0.30 | -30.57 ± 0.32 | -30.69 ± 0.31 |
| Change at Month 51 | -31.09 ± 0.32 | -30.50 ± 0.33 | -30.74 ± 0.33 |
| Change at Month 54 | -31.03 ± 0.32 | -31.38 ± 0.33 | -31.02 ± 0.33 |
| Change at Month 57 | -30.62 ± 0.40 | -30.75 ± 0.41 | -30.95 ± 0.41 |
| Change at Month 60 | -31.74 ± 0.45 | -30.57 ± 0.45 | -31.31 ± 0.47 |
| Change at Month 63 | -31.23 ± 0.58 | -31.08 ± 0.57 | -31.65 ± 0.60 |
ACR-EULAR Boolean-based definition of remission participant must satisfy all of the following: TJC28 \<=1, SJC28 \<=1, CRP \<=10 mg/L, PtGA on a 0-100 mm scale, higher scores indicate greater affection due to disease activity.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Month 2 | 3.83 | 4.99 | 3.22 |
| Month 3 | 5.73 | 7.72 | 6.10 |
| Month 6 | 9.10 | 10.66 | 7.80 |
| Month 9 | 10.85 | 12.60 | 8.96 |
| Month 12 | 11.22 | 13.06 | 9.12 |
| Month 15 | 12.56 | 15.18 | 10.28 |
| Month 18 | 12.10 | 16.04 | 11.78 |
| Month 21 | 12.90 | 15.22 | 13.45 |
| Month 24 | 13.60 | 15.99 | 13.35 |
| Month 27 | 13.24 | 17.59 | 14.82 |
| Month 30 | 13.46 | 16.96 | 14.31 |
| Month 33 | 13.88 | 15.97 | 14.82 |
| Month 36 | 14.51 | 16.18 | 14.53 |
| Month 39 | 13.78 | 14.30 | 15.15 |
| Month 42 | 14.79 | 15.41 | 15.01 |
| Month 45 | 14.89 | 15.46 | 15.74 |
| Month 48 | 15.14 | 13.90 | 17.28 |
| Month 51 | 14.33 | 15.50 | 16.26 |
| Month 54 | 14.01 | 16.42 | 16.36 |
| Month 57 | 15.54 | 14.16 | 15.08 |
| Month 60 | 11.31 | 12.73 | 15.58 |
| Month 63 | 11.76 | 16.96 | 15.25 |
| Month 66 | 9.02 | 16.79 | 13.11 |
| Month 69 | 13.04 | 19.57 | 14.58 |
| Month 72 | 8.33 | 22.22 | 13.33 |
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Month 2 | 4.62 | 7.03 | 4.15 |
| Month 3 | 9.19 | 11.14 | 7.84 |
| Month 6 | 12.38 | 14.23 | 10.40 |
| Month 9 | 15.90 | 17.72 | 12.75 |
| Month 12 | 15.89 | 18.69 | 13.92 |
| Month 15 | 18.26 | 20.29 | 15.90 |
| Month 18 | 18.68 | 21.96 | 16.79 |
| Month 21 | 20.89 | 22.07 | 17.93 |
| Month 24 | 20.44 | 22.76 | 18.93 |
| Month 27 | 21.91 | 23.62 | 21.12 |
| Month 30 | 21.31 | 23.68 | 21.91 |
| Month 33 | 21.43 | 25.06 | 22.19 |
| Month 36 | 22.47 | 24.35 | 21.80 |
| Month 39 | 22.99 | 24.21 | 21.48 |
| Month 42 | 24.59 | 24.23 | 23.41 |
| Month 45 | 25.27 | 23.20 | 23.26 |
| Month 48 | 25.32 | 23.20 | 24.20 |
| Month 51 | 23.35 | 23.85 | 24.24 |
| Month 54 | 22.34 | 24.09 | 24.55 |
| Month 57 | 24.10 | 23.82 | 24.83 |
| Month 60 | 18.65 | 20.30 | 25.23 |
| Month 63 | 19.00 | 23.48 | 23.32 |
| Month 66 | 14.75 | 21.37 | 20.49 |
| Month 69 | 17.39 | 17.39 | 22.92 |
| Month 72 | 16.67 | 22.22 | 13.33 |
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Month 2 | 4.70 | 7.40 | 4.36 |
| Month 3 | 9.26 | 11.06 | 7.76 |
| Month 6 | 12.87 | 14.31 | 10.32 |
| Month 9 | 15.76 | 18.09 | 13.25 |
| Month 12 | 16.33 | 18.62 | 14.64 |
| Month 15 | 18.03 | 21.36 | 16.41 |
| Month 18 | 19.82 | 22.12 | 17.93 |
| Month 21 | 21.35 | 22.55 | 18.70 |
| Month 24 | 20.44 | 22.76 | 19.48 |
| Month 27 | 22.77 | 23.29 | 21.51 |
| Month 30 | 21.88 | 24.18 | 22.31 |
| Month 33 | 22.24 | 25.91 | 22.36 |
| Month 36 | 23.22 | 25.30 | 21.64 |
| Month 39 | 23.92 | 24.30 | 21.90 |
| Month 42 | 25.02 | 24.95 | 23.66 |
| Month 45 | 25.95 | 24.23 | 23.85 |
| Month 48 | 25.55 | 24.44 | 24.31 |
| Month 51 | 24.50 | 24.89 | 25.11 |
| Month 54 | 23.23 | 25.00 | 25.45 |
| Month 57 | 24.32 | 24.04 | 25.75 |
| Month 60 | 19.88 | 20.91 | 26.48 |
| Month 63 | 20.81 | 22.17 | 22.87 |
| Month 66 | 13.93 | 22.14 | 17.21 |
| Month 69 | 19.57 | 19.57 | 18.75 |
| Month 72 | 16.67 | 22.22 | 13.33 |
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Month 2 | 30.76 | 35.02 | 28.08 |
| Month 3 | 41.47 | 45.00 | 37.99 |
| Month 6 | 50.85 | 53.56 | 45.80 |
| Month 9 | 56.40 | 59.82 | 52.90 |
| Month 12 | 57.87 | 61.11 | 54.93 |
| Month 15 | 61.12 | 63.92 | 57.39 |
| Month 18 | 62.10 | 65.19 | 60.41 |
| Month 21 | 62.75 | 65.26 | 61.21 |
| Month 24 | 63.17 | 66.15 | 61.59 |
| Month 27 | 65.17 | 66.97 | 63.67 |
| Month 30 | 67.23 | 68.35 | 65.64 |
| Month 33 | 65.75 | 68.82 | 65.36 |
| Month 36 | 67.33 | 66.61 | 65.48 |
| Month 39 | 69.74 | 67.11 | 66.03 |
| Month 42 | 68.96 | 70.72 | 66.41 |
| Month 45 | 68.36 | 68.97 | 67.55 |
| Month 48 | 67.28 | 64.76 | 67.94 |
| Month 51 | 67.91 | 67.51 | 67.78 |
| Month 54 | 64.89 | 68.61 | 68.00 |
| Month 57 | 63.51 | 66.29 | 68.21 |
| Month 60 | 63.30 | 66.67 | 64.17 |
| Month 63 | 61.54 | 68.26 | 64.57 |
| Month 66 | 59.02 | 71.76 | 59.02 |
| Month 69 | 60.87 | 65.22 | 68.75 |
| Month 72 | 50.00 | 66.67 | 60.00 |
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Month 2 | 29.47 | 34.25 | 26.92 |
| Month 3 | 40.07 | 43.90 | 35.99 |
| Month 6 | 49.36 | 51.83 | 43.63 |
| Month 9 | 55.40 | 58.78 | 50.91 |
| Month 12 | 56.56 | 59.38 | 53.57 |
| Month 15 | 60.31 | 62.70 | 55.93 |
| Month 18 | 60.51 | 64.02 | 59.42 |
| Month 21 | 61.37 | 64.94 | 60.20 |
| Month 24 | 62.78 | 65.25 | 61.19 |
| Month 27 | 64.93 | 66.39 | 62.87 |
| Month 30 | 67.15 | 67.84 | 65.00 |
| Month 33 | 65.50 | 67.71 | 65.03 |
| Month 36 | 66.67 | 65.15 | 64.66 |
| Month 39 | 68.64 | 66.40 | 65.61 |
| Month 42 | 68.44 | 69.10 | 65.82 |
| Month 45 | 67.97 | 68.66 | 67.16 |
| Month 48 | 66.71 | 63.15 | 67.58 |
| Month 51 | 67.77 | 65.87 | 67.63 |
| Month 54 | 64.54 | 67.88 | 68.00 |
| Month 57 | 62.61 | 65.39 | 67.98 |
| Month 60 | 63.00 | 65.15 | 65.42 |
| Month 63 | 62.90 | 66.52 | 66.37 |
| Month 66 | 57.38 | 67.94 | 61.48 |
| Month 69 | 58.70 | 65.22 | 66.67 |
| Month 72 | 50.00 | 66.67 | 53.33 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis based on a 28-joint assessment. DAS28-4 (CRP) was calculated from number of painful joints out of 28 joints (TJC28) and number of swollen joints out of 28 joints (SJC28), CRP (mg/L) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (CRP) score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 indicates low disease activity and \> 3.2 to \<=5.1 indicates moderate disease activity, \>5.1 indicates high disease activity, and DAS28-4 (CRP) \< 2.6 indicates remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96.
| percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Month 2 | 31.55 | 35.57 | 28.36 |
| Month 3 | 41.68 | 46.05 | 37.54 |
| Month 6 | 50.28 | 54.87 | 44.88 |
| Month 9 | 56.11 | 59.01 | 50.91 |
| Month 12 | 57.73 | 60.06 | 53.05 |
| Month 15 | 60.38 | 63.54 | 55.03 |
| Month 18 | 61.72 | 63.86 | 58.51 |
| Month 21 | 62.29 | 63.67 | 59.27 |
| Month 24 | 61.93 | 64.11 | 59.78 |
| Month 27 | 64.22 | 67.63 | 60.56 |
| Month 30 | 64.66 | 65.49 | 63.22 |
| Month 33 | 63.80 | 66.02 | 62.82 |
| Month 36 | 64.43 | 64.63 | 62.59 |
| Month 39 | 65.85 | 65.18 | 63.53 |
| Month 42 | 65.43 | 67.93 | 65.31 |
| Month 45 | 64.74 | 65.77 | 64.52 |
| Month 48 | 64.39 | 64.52 | 64.36 |
| Month 51 | 65.19 | 66.47 | 65.46 |
| Month 54 | 64.18 | 66.24 | 66.55 |
| Month 57 | 63.06 | 63.60 | 67.29 |
| Month 60 | 62.69 | 64.24 | 65.11 |
| Month 63 | 60.18 | 64.35 | 68.61 |
| Month 66 | 55.74 | 66.41 | 60.66 |
| Month 69 | 58.70 | 56.52 | 70.83 |
| Month 72 | 50.00 | 61.11 | 73.33 |
ACR20 response is a \>= 20% improvement in TJC (28) and SJC (28) and \>=20% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Month 2 | 832 | 867 | 812 |
| Month 3 | 979 | 992 | 923 |
| Month 6 | 999 | 1012 | 981 |
| Month 9 | 1019 | 1004 | 987 |
| Month 12 | 1033 | 992 | 966 |
| Month 15 | 1017 | 1003 | 969 |
| Month 18 | 981 | 974 | 937 |
| Month 21 | 955 | 953 | 949 |
| Month 24 | 956 | 922 | 922 |
| Month 27 | 961 | 917 | 913 |
| Month 30 | 932 | 899 | 931 |
| Month 33 | 935 | 888 | 922 |
| Month 36 | 907 | 881 | 887 |
| Month 39 | 896 | 843 | 887 |
| Month 42 | 905 | 848 | 883 |
| Month 45 | 780 | 718 | 790 |
| Month 48 | 654 | 587 | 639 |
| Month 51 | 535 | 485 | 518 |
| Month 54 | 434 | 396 | 400 |
| Month 57 | 337 | 321 | 302 |
| Month 60 | 243 | 237 | 232 |
| Month 63 | 163 | 166 | 161 |
| Month 66 | 85 | 101 | 89 |
| Month 69 | 26 | 36 | 37 |
| Month 72 | 5 | 15 | 10 |
ACR50 response is a \>= 50% improvement in TJC (28) and SJC (28) and \>=50% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Month 2 | 402 | 452 | 336 |
| Month 3 | 528 | 561 | 460 |
| Month 6 | 605 | 614 | 533 |
| Month 9 | 620 | 651 | 577 |
| Month 12 | 631 | 654 | 577 |
| Month 15 | 652 | 668 | 582 |
| Month 18 | 633 | 643 | 609 |
| Month 21 | 607 | 623 | 608 |
| Month 24 | 622 | 616 | 592 |
| Month 27 | 620 | 602 | 596 |
| Month 30 | 599 | 609 | 610 |
| Month 33 | 585 | 611 | 594 |
| Month 36 | 603 | 566 | 592 |
| Month 39 | 595 | 588 | 561 |
| Month 42 | 592 | 578 | 587 |
| Month 45 | 521 | 481 | 519 |
| Month 48 | 422 | 385 | 424 |
| Month 51 | 350 | 320 | 346 |
| Month 54 | 284 | 271 | 268 |
| Month 57 | 200 | 210 | 209 |
| Month 60 | 152 | 151 | 150 |
| Month 63 | 100 | 104 | 103 |
| Month 66 | 52 | 68 | 55 |
| Month 69 | 16 | 20 | 27 |
| Month 72 | 3 | 6 | 7 |
ACR70 response is a \>= 70% improvement in TJC (28) and SJC (28) and \>=70% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Month 2 | 152 | 193 | 113 |
| Month 3 | 253 | 268 | 199 |
| Month 6 | 282 | 331 | 234 |
| Month 9 | 328 | 367 | 291 |
| Month 12 | 337 | 373 | 284 |
| Month 15 | 359 | 390 | 304 |
| Month 18 | 358 | 382 | 325 |
| Month 21 | 362 | 370 | 322 |
| Month 24 | 349 | 386 | 328 |
| Month 27 | 374 | 390 | 342 |
| Month 30 | 369 | 397 | 358 |
| Month 33 | 357 | 392 | 355 |
| Month 36 | 362 | 343 | 351 |
| Month 39 | 371 | 361 | 338 |
| Month 42 | 376 | 342 | 343 |
| Month 45 | 313 | 298 | 298 |
| Month 48 | 256 | 228 | 238 |
| Month 51 | 216 | 195 | 199 |
| Month 54 | 159 | 163 | 160 |
| Month 57 | 128 | 127 | 118 |
| Month 60 | 79 | 83 | 92 |
| Month 63 | 58 | 57 | 64 |
| Month 66 | 25 | 38 | 35 |
| Month 69 | 8 | 15 | 14 |
| Month 72 | 2 | 5 | 4 |
HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.
| units on a scale | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Change at Month 2 | -0.42 ± 0.02 | -0.45 ± 0.02 | -0.38 ± 0.02 |
| Change at Month 3 | -0.45 ± 0.02 | -0.48 ± 0.02 | -0.42 ± 0.02 |
| Change at Month 6 | -0.50 ± 0.02 | -0.51 ± 0.02 | -0.46 ± 0.02 |
| Change at Month 9 | -0.51 ± 0.02 | -0.55 ± 0.02 | -0.47 ± 0.02 |
| Change at Month 12 | -0.52 ± 0.02 | -0.53 ± 0.02 | -0.49 ± 0.02 |
| Change at Month 15 | -0.53 ± 0.02 | -0.56 ± 0.02 | -0.51 ± 0.02 |
| Change at Month 18 | -0.52 ± 0.02 | -0.56 ± 0.02 | -0.49 ± 0.02 |
| Change at Month 21 | -0.53 ± 0.02 | -0.55 ± 0.02 | -0.50 ± 0.02 |
| Change at Month 24 | -0.52 ± 0.02 | -0.57 ± 0.02 | -0.49 ± 0.02 |
| Change at Month 27 | -0.52 ± 0.02 | -0.56 ± 0.02 | -0.51 ± 0.02 |
| Change at Month 30 | -0.53 ± 0.02 | -0.55 ± 0.02 | -0.50 ± 0.02 |
| Change at Month 33 | -0.51 ± 0.02 | -0.56 ± 0.02 | -0.52 ± 0.02 |
| Change at Month 36 | -0.50 ± 0.02 | -0.54 ± 0.02 | -0.48 ± 0.02 |
| Change at Month 39 | -0.51 ± 0.02 | -0.54 ± 0.02 | -0.49 ± 0.02 |
| Change at Month 42 | -0.51 ± 0.02 | -0.52 ± 0.02 | -0.50 ± 0.02 |
| Change at Month 45 | -0.50 ± 0.02 | -0.51 ± 0.02 | -0.51 ± 0.02 |
| Change at Month 48 | -0.50 ± 0.02 | -0.50 ± 0.02 | -0.48 ± 0.02 |
| Change at Month 51 | -0.53 ± 0.02 | -0.49 ± 0.02 | -0.50 ± 0.02 |
| Change at Month 54 | -0.53 ± 0.02 | -0.51 ± 0.02 | -0.48 ± 0.02 |
| Change at Month 57 | -0.49 ± 0.02 | -0.48 ± 0.02 | -0.48 ± 0.02 |
| Change at Month 60 | -0.52 ± 0.03 | -0.49 ± 0.03 | -0.48 ± 0.03 |
| Change at Month 63 | -0.54 ± 0.03 | -0.48 ± 0.03 | -0.48 ± 0.04 |
Collected over Baseline up to last contact date (maximum up to 72 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 5 mg BID | 49/1,455 (3.4%) | 373/1,455 (25.6%) | 1,108/1,455 (76.2%) |
| Tofacitinib 10 mg BID | 66/1,456 (4.5%) | 420/1,456 (28.8%) | 1,127/1,456 (77.4%) |
| TNFi | 38/1,451 (2.6%) | 339/1,451 (23.4%) | 1,056/1,451 (72.8%) |
| Event | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| PneumoniaInfections and infestations | 50/1455 | 56/1456 | 43/1451 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 29/1455 | 23/1456 | 16/1451 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 10/1455 | 22/1456 | 1/1451 |
| CellulitisInfections and infestations | 12/1455 | 13/1456 | 15/1451 |
| Urinary tract infectionInfections and infestations | 14/1455 | 14/1456 | 9/1451 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 11/1455 | 10/1456 | 12/1451 |
| Femur fractureInjury, poisoning and procedural complications | 10/1455 | 5/1456 | 11/1451 |
| Herpes zosterInfections and infestations | 9/1455 | 11/1456 | 2/1451 |
| BronchitisInfections and infestations | 10/1455 | 9/1456 | 7/1451 |
| AnaemiaBlood and lymphatic system disorders | 9/1455 | 4/1456 | 1/1451 |
| Event | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 319/1455 | 318/1456 | 264/1451 |
| BronchitisInfections and infestations | 221/1455 | 243/1456 | 168/1451 |
| Urinary tract infectionInfections and infestations | 190/1455 | 220/1456 | 186/1451 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 183/1455 | 188/1456 | 202/1451 |
| FallInjury, poisoning and procedural complications | 177/1455 | 160/1456 | 159/1451 |
| Herpes zosterInfections and infestations | 175/1455 | 160/1456 | 59/1451 |
| NasopharyngitisInfections and infestations | 168/1455 | 172/1456 | 164/1451 |
| HypertensionVascular disorders | 129/1455 | 152/1456 | 127/1451 |
| LymphopeniaBlood and lymphatic system disorders | 107/1455 | 151/1456 | 36/1451 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 111/1455 | 90/1456 | 124/1451 |
Safety Analysis Set (SAS) included all participants who were randomized in the study and received at least one dose of the randomized investigational drug (tofacitinib or TNFi).
| Age, Continuous(years) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi | Total |
|---|---|---|---|---|
| Mean | 60.75 ± 6.80 | 61.40 ± 7.07 | 61.30 ± 7.47 | 61.15 ± 7.12 |
| Sex: Female, Male(Participants) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi | Total |
|---|---|---|---|---|
| Female | 1169 | 1124 | 1117 | 3410 |
| Male | 286 | 332 | 334 | 952 |
| Ethnicity (NIH/OMB)(Participants) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi | Total |
|---|---|---|---|---|
| Hispanic or Latino | 438 | 482 | 470 | 1390 |
| Not Hispanic or Latino | 1017 | 974 | 981 | 2972 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | TNFi | Total |
|---|---|---|---|---|
| Race — White | 1128 | 1126 | 1099 | 3353 |
| Race — Black or African American | 63 | 65 | 83 | 211 |
| Race — Asian | 65 | 56 | 55 | 176 |
| Race — Other | 199 | 209 | 214 | 622 |
Showing the first 100 of 345 sites across 30 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2014 to primary completion in Jul 2020, 76 months.
Results were first posted in Aug 2021, 1 year after primary completion.
Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 76 months is above that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib